Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annonc.2021.07.011 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum 'ribociclib
4
'ribociclib fulvestrant
4
fulvestrant postmenopausal
4
postmenopausal women
4
women hormone
4
hormone receptor-positive
4
receptor-positive human
4
human epidermal
4
epidermal growth
4
growth factor
4
Similar Publications
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Ann Oncol
October 2021
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany.
Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
Eur J Med Chem
June 2020
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, I-35131, Padova, Italy. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!